LUPIN News Today

Lupin Ltd Share Price

LUPIN

CMP as on 03-May-24 12:00
₹ 1,655

icon 7.10 | 0.43%

Open
₹ 1,654
Turnover(lac)
₹ 15,970
Prev. Close
₹ 1,647.65
Day's Vol (shares)
₹ 965,116
Day's Vol (shares)
₹ 1,648.00         ₹ 1,683.00

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
Image not found

Lupin's Aurangabad facility gets zero adverse observations in US FDA's latest inspection

Lupin disclosed in a regulatory filing that a meeting of the Board of Directors is scheduled for Monday, May 6, 2024, to discuss and approve the audited financial results for the quarter and year-ended March 31, 2024, and to consider recommending dividends, if applicable.

  • 24 Apr, 2024 |
  • 11:33 AM
Image not found

Lupin Launches Generic Mybetriq in US, Eyes Robust Sales Growth

Myrbetriq, a prescription medicine, is used to treat overactive bladder symptoms like frequent or urgent urination and urinary incontinence, including neurogenic detrusor overactivity (NDO) in children.

  • 22 Apr, 2024 |
  • 3:21 PM
Image not found

Lupin launches generic version of doxycycline capsules in the US

The business got Form 483 from the USFDA in March, with one observation for its Aurangabad plant, following an inspection from March 6 to March 15.

  • 10 Apr, 2024 |
  • 2:28 PM
Image not found

Lupin names Christoph Funke as new Chief Technical Officer

He will be located in Mumbai and would be in charge of Lupin's technical operations.

  • 19 Mar, 2024 |
  • 11:06 AM
Image not found

Lupin launches generic fertility drug Ganirelix Acetate in the US

It is the generic equivalent of Organon USA LLC's Ganirelix Acetate Injection, 250 mcg/0.5 mL, which is reference listed (RLD).

  • 16 Feb, 2024 |
  • 9:26 AM
Image not found

Q3FY24 Review: Lupin: Aspiring for further margin expansion

Recommendation: Add; Target price: ₹1590

  • 09 Feb, 2024 |
  • 1:34 PM
Image not found

Lupin Soars: Q3 Revenue Up 20%, Net Profit Quadruples to ₹613 Crore

Revenue increased to ₹5,197.4 Crore from ₹4,322.2 Crore in the same quarter last year.

  • 08 Feb, 2024 |
  • 11:47 AM
Image not found

USFDA Nod for Stroke Drug Lifts Lupin Shares: Indian Pharma Giant Celebrates

Lupin was trading at Rs 1,455.55 on the BSE at 11:13 a.m., up Rs 16.25, or 1.15% .

  • 24 Jan, 2024 |
  • 11:11 AM
Image not found

Lupin Hits 52-Week High as FDA Greenlights Febuxostat Tablets for Gout Treatment in the U.S.

Febuxostat Tablets, with indications for managing hyperuricemia in adult gout patients, will be manufactured at Lupin's Pithampur facility in India

  • 19 Jan, 2024 |
  • 10:53 AM
Image not found

Lupin zooms ~2% on gaining USFDA approval for hypertension drug

Lupin has obtained approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA)

  • 15 Jan, 2024 |
  • 2:29 PM